Objective:To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor(G-CSF) in breast cancer patients.Methods:A total of 57 breast cancer patients were treated with docetaxel 120 mg/m2.When the white blood cell(WBC) count decreased to 1.0×109/L,patients were given G-CSF 5-g/kg daily by subcutaneous injection until the end of apheresis.Peripheral blood mononuclear cells(MNC) were isolated by Cobe Spectra Apheresis System.The percentage of CD34+ cell was assayed by flow cytometry.Results:At a median 6 of days(range 3-8) after the administration of docetaxel,the median WBC count decreased to 1.08×109/L(range 0.20-2.31).The median duration of G-CSF mobilization was 3 days(range 2-7).The MNC collection was conducted 8-12 days(median 10 days) after docetaxel treatment.The median MNC was 5.35×108/kg(range 0.59-14.07),the median CD34+ cell count was 2.43×106/kg(range 0.16-16.69).The CD34+ cell count was higher than 1.00×106/kg in 47 of 57 cases(82.46%) and higher than 2.00×106/kg in 36 cases(63.16%).The CD34+ cell count was higher than 2.00×106/kg in 27 collections(23.68%).The MNC count and the CD34+ cell count were correlated with the bottom of WBC after docetaxel chemotherapy(r=0.364,0.502,P=0.005,0.000).The CD34+ cell count was correlated with the MNC count(r=0.597,P=0.000).The mobilization and apheresis were well tolerated in all patients.Mild perioral numbness and numbness of hand or feet were observed in 3 cases.No serious adverse events were reported.Conclusion:Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients. Objective: To evaluate the effectiveness and safety of the mobilization of peripheral blood hematopoietic stem cells by combining docetaxel with granulocyte colony-stimulating factor (G-CSF) in breast cancer patients. Methods: A total of 57 breast cancer patients were treated with docetaxel 120 mg / m2.When the white blood cell (WBC) count decreased to 1.0 × 109 / L, patients were given G-CSF 5-g / kg daily by subcutaneous injection until the end of apheresis. Peripheral blood mononuclear cells isolated by Cobe Spectra Apheresis System. The percentage of CD34 + cell was assayed by flow cytometry. Results: At a median 6 of days (range 3-8) after the administration of docetaxel, the median WBC count decreased to 1.08 × 109 / L ( range 0.20-2.31). The median duration of G-CSF mobilization was 3 days (range 2-7). MNC collection was conducted for 8-12 days (median 10 days) after docetaxel treatment. median MNC was 5.35 × 108 / kg (range 0.59-14.07), the median CD34 + cell count was 2.43 × 106 / kg (range 0.16-16.69) The CD34 + cell count was higher than 1.00 × 106 / kg in 47 of 57 cases (82.46%) and higher than 2.00 × 106 / kg in 36 cases (63.16%). The CD34 + cell count was higher than 2.00 × 106 / kg in 27 collections (23.68%). The MNC count and the CD34 + cell count were correlated with the bottom of WBC after docetaxel chemotherapy (r = 0.364, 0.502, P = 0.005,0.000) (r = 0.597, P = 0.000) .The mobilization and apheresis were well tolerated in all patients. Child perioral numbness and numbness of hand or feet were observed in 3 cases. No serious adverse events were reported. Confusion: Mobilization of peripheral blood hematopoietic stem cell by combining docetaxel with G-CSF was effective and safety in breast cancer patients.